AbbVie's new HIV drug Class 1 approved for clinical trials in China
On July 29th, the China National Medical Products Administration's Center for Drug Evaluation (CDE) website announced that AbbVie's Class 1 new drug ABBV-382 injection has been approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally. This is the first time this investigational drug has been approved for clinical trials in China. According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an HIV virus control regimen for antiretroviral therapy (ART), currently in phase 2 clinical trials
According to the Zhitong Finance and Economics APP, on July 29th, the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that AbbVie (ABBV.US) Class 1 new drug ABBV-382 injection was approved for clinical trials. It is intended to be developed for the continuous suppression of immune-mediated HIV (HIV plasma viral load at undetectable levels) without combination antiretroviral therapy (ART). Public information shows that ABBV-382 is an α4β7 integrin monoclonal antibody, currently in phase 2 clinical trials globally, and this is the first time this investigational drug has been approved for clinical trials in China.
According to AbbVie's official website, the company is developing a combination of ABBV-181 (budigalimab, anti-PD-1) and ABBV-382 (research code: ABBV-1882), studying it as an antiretroviral therapy (ART) for HIV virus control, currently in phase 2 clinical trials
